Sponsored
Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, outlines the deciding factors biotechs should consider when selecting a contract development and manufacturing organization (CDMO) partner.
Sponsored
Successful tech transfer begins with early alignment, clear scope definition, and proactive risk management to ensure smooth progression from development to GMP manufacturing. By combining global expertise with local execution, Rentschler Biopharma delivers consistent quality, operational flexibility, and reduced risk for clients advancing complex therapies.
Sponsored Content
Rentschler Biopharma is evolving its CDMO capabilities through strategic partnerships, infrastructure investments, and sustainability initiatives to better support clients' complex biologics programs.
Sponsored Video
Christiane Bardroff, Chief Operating Officer and Patrick Meyer Global Head of Business Development—both at Rentschler Biopharma SE —share their insights into the company’s client-centric approach.
Sponsored Video
Benedikt von Braunmühl, CEO of Rentschler Biopharma, discusses the company's strategic shift toward biologics CDMO services.
